MedPath

Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Completed
Conditions
Diabetes
Diabetes Mellitus, Type 2
Interventions
Registration Number
NCT01226966
Lead Sponsor
Novo Nordisk A/S
Brief Summary

This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
3152
Inclusion Criteria
  • Patients diagnosed with type 2 diabetes
  • Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment
Exclusion Criteria
  • Hypersensitivity (allergy) to liraglutide or to any of the excipients
  • Patient is participating in a clinical trial at the inclusion
  • Type 1 diabetes

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Aliraglutide-
Primary Outcome Measures
NameTimeMethod
Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0%Month 24
Secondary Outcome Measures
NameTimeMethod
Change in Body Weight at Month 18Month 0, Month 18
Change in HbA1c at month 6Month 0, Month 6
Change in HbA1c at month 3Month 0, Month 3
Change in HbA1c at month 12Month 0, Month 12
Change in fasting plasma glucose (FPG) at month 12Month 0, Month 12
Change in Body Weight at Month 3Month 0, Month 3
Change in Body Weight at Month 24Month 0, Month 24
Change in HbA1c at month 24Month 0, Month 24
Change in fasting plasma glucose (FPG) at month 3Month 0, Month 3
Change in fasting plasma glucose (FPG) at month 6Month 0, Month 6
Change in fasting plasma glucose (FPG) at month 18Month 0, Month 18
Change in HbA1c at month 18Month 0, Month 18
Change in fasting plasma glucose (FPG) at month 24Month 0, Month 24
Change in Body Weight at Month 12Month 0, Month 12
Change in Body Weight at Month 6Month 0, Month 6

Trial Locations

Locations (1)

Novo Nordisk Investigational Site

🇫🇷

Paris La défense cedex, France

© Copyright 2025. All Rights Reserved by MedPath